会員登録
ログイン
【4884】クリングルファーマ
HGF(肝細胞増殖因子)タンパク質を用いた難治性疾患の治療薬の研究 開発
類似企業：
【業界1位】
武田薬品工業
【業界1位】
武田薬品工業
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026.09 | 2025/11/12 | 当初予 | 72 | - | - | - | -1,172 | - | - | - | -1,172 | - | - | - | -1,173 | - | - | - |
| 2025.09 | 2025/11/12 | 実 | 72 | ↑ | +1.4% | -73.5% | -909 | ↑ | +3.2% | +34.1% | -914 | ↑ | +3.3% | +33.7% | -916 | ↑ | +3.2% | +33.6% |
| 2025.09 | 2025/08/08 | Q3予 | 71 | → | 0.0% | -73.9% | -939 | → | 0.0% | +31.9% | -945 | → | 0.0% | +31.5% | -946 | → | 0.0% | +31.4% |
| 2025.09 | 2025/07/16 | 修正予 | 71 | ↓ | -73.9% | -73.9% | -939 | ↑ | +31.9% | +31.9% | -945 | ↑ | +31.5% | +31.5% | -946 | ↑ | +31.4% | +31.4% |
| 2025.09 | 2025/05/12 | Q2予 | 272 | → | 0.0% | 0.0% | -1,379 | → | 0.0% | 0.0% | -1,379 | → | 0.0% | 0.0% | -1,380 | → | 0.0% | 0.0% |
| 2025.09 | 2025/02/07 | Q1予 | 272 | → | 0.0% | 0.0% | -1,379 | → | 0.0% | 0.0% | -1,379 | → | 0.0% | 0.0% | -1,380 | → | 0.0% | 0.0% |
| 2025.09 | 2024/11/13 | 当初予 | 272 | - | - | - | -1,379 | - | - | - | -1,379 | - | - | - | -1,380 | - | - | - |
| 2024.09 | 2024/11/13 | 実 | 80 | ↑ | +1.3% | -70.6% | -817 | ↑ | +18.5% | +27.9% | -754 | ↑ | +19.8% | +31.9% | -756 | ↑ | +19.7% | +31.8% |
| 2024.09 | 2024/08/09 | Q3予 | 79 | ↓ | -71.0% | -71.0% | -1,003 | ↑ | +11.5% | +11.5% | -940 | ↑ | +15.1% | +15.1% | -942 | ↑ | +15.1% | +15.1% |
| 2024.09 | 2024/05/13 | Q2予 | 272 | → | 0.0% | 0.0% | -1,133 | → | 0.0% | 0.0% | -1,107 | → | 0.0% | 0.0% | -1,109 | → | 0.0% | 0.0% |
| 2024.09 | 2024/02/09 | Q1予 | 272 | → | 0.0% | 0.0% | -1,133 | → | 0.0% | 0.0% | -1,107 | → | 0.0% | 0.0% | -1,109 | → | 0.0% | 0.0% |
| 2024.09 | 2023/11/13 | 当初予 | 272 | - | - | - | -1,133 | - | - | - | -1,107 | - | - | - | -1,109 | - | - | - |
| 2023.09 | 2023/11/13 | 実 | 69 | ↑ | +1.5% | +1.5% | -888 | ↑ | +10.6% | +10.6% | -852 | ↑ | +10.6% | +10.6% | -854 | ↑ | +10.6% | +10.6% |
| 2023.09 | 2023/08/14 | Q3予 | 68 | → | 0.0% | 0.0% | -993 | → | 0.0% | 0.0% | -953 | → | 0.0% | 0.0% | -955 | → | 0.0% | 0.0% |
| 2023.09 | 2023/05/15 | Q2予 | 68 | → | 0.0% | 0.0% | -993 | → | 0.0% | 0.0% | -953 | → | 0.0% | 0.0% | -955 | → | 0.0% | 0.0% |
| 2023.09 | 2023/02/10 | Q1予 | 68 | → | 0.0% | 0.0% | -993 | → | 0.0% | 0.0% | -953 | → | 0.0% | 0.0% | -955 | → | 0.0% | 0.0% |
| 2023.09 | 2022/11/14 | 当初予 | 68 | - | - | - | -993 | - | - | - | -953 | - | - | - | -955 | - | - | - |
| 2022.09 | 2022/11/14 | 実 | 391 | ↑ | +9.5% | +10.1% | -426 | ↑ | +14.3% | +68.6% | -330 | ↑ | +21.2% | +75.7% | -331 | ↑ | +21.4% | +74.5% |
| 2022.09 | 2022/08/12 | Q3予 | 357 | ↑ | +0.6% | +0.6% | -497 | ↑ | +63.4% | +63.4% | -419 | ↑ | +67.6% | +69.1% | -421 | ↑ | +67.5% | +67.5% |
| 2022.09 | 2022/05/13 | Q2予 | 355 | → | 0.0% | 0.0% | -1,357 | → | 0.0% | 0.0% | -1,295 | → | 0.0% | +4.6% | -1,297 | → | 0.0% | 0.0% |
| 2022.09 | 2022/02/14 | Q1予 | 355 | → | 0.0% | 0.0% | -1,357 | → | 0.0% | 0.0% | -1,295 | ↑ | +4.6% | +4.6% | -1,297 | → | 0.0% | 0.0% |
| 2022.09 | 2021/11/12 | 当初予 | 355 | - | - | - | -1,357 | - | - | - | -1,357 | - | - | - | -1,297 | - | - | - |
| 2021.09 | 2021/11/12 | 実 | 289 | ↑ | +4.3% | +40.3% | -357 | ↑ | +8.0% | +65.6% | -299 | ↑ | +8.8% | +70.5% | -301 | ↑ | +8.8% | +70.4% |
| 2021.09 | 2021/08/13 | Q3予 | 277 | ↑ | +34.5% | +34.5% | -388 | ↑ | +62.6% | +62.6% | -328 | ↑ | +67.7% | +67.7% | -330 | ↑ | +67.6% | +67.6% |
| 2021.09 | 2021/05/14 | Q2予 | 206 | → | 0.0% | 0.0% | -1,037 | → | 0.0% | 0.0% | -1,015 | → | 0.0% | 0.0% | -1,017 | → | 0.0% | 0.0% |
| 2021.09 | 2021/02/12 | 当初予 | 206 | - | - | - | -1,037 | - | - | - | -1,015 | - | - | - | -1,017 | - | - | - |
